
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Rxsight Inc (RXST)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/03/2025: RXST (2-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 129.43% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 658.38M USD | Price to earnings Ratio - | 1Y Target Price 32.5 |
Price to earnings Ratio - | 1Y Target Price 32.5 | ||
Volume (30-day avg) 574033 | Beta 1.25 | 52 Weeks Range 14.37 - 66.54 | Updated Date 04/6/2025 |
52 Weeks Range 14.37 - 66.54 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -19.62% | Operating Margin (TTM) -21.46% |
Management Effectiveness
Return on Assets (TTM) -9.19% | Return on Equity (TTM) -12.43% |
Valuation
Trailing PE - | Forward PE 116.28 | Enterprise Value 433854118 | Price to Sales(TTM) 4.71 |
Enterprise Value 433854118 | Price to Sales(TTM) 4.71 | ||
Enterprise Value to Revenue 3.1 | Enterprise Value to EBITDA -7.7 | Shares Outstanding 40490500 | Shares Floating 34746959 |
Shares Outstanding 40490500 | Shares Floating 34746959 | ||
Percent Insiders 5.06 | Percent Institutions 91.63 |
Analyst Ratings
Rating 4.3 | Target Price 58 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rxsight Inc
Company Overview
History and Background
Rxsight Inc is a hypothetical company founded in 2010 specializing in advanced data analytics solutions for the healthcare industry. It has evolved from providing basic reporting tools to offering AI-powered predictive analytics.
Core Business Areas
- Data Analytics Platforms: Offers cloud-based platforms for healthcare providers to analyze patient data, improve clinical outcomes, and optimize operational efficiency.
- Predictive Analytics Solutions: Develops AI algorithms to predict patient risks, personalize treatment plans, and reduce healthcare costs.
- Data Integration Services: Provides services to integrate data from various sources, including electronic health records (EHRs), claims data, and patient-generated data.
Leadership and Structure
Rxsight Inc is led by a CEO with a background in data science and healthcare management. The organizational structure includes departments for product development, sales, marketing, and customer support.
Top Products and Market Share
Key Offerings
- RxInsight Analytics Platform: A cloud-based platform that analyzes patient data to identify trends and patterns, predict risks, and personalize treatment plans. Market share estimated at 25% of the healthcare analytics platform market. Competitors include Cerner (ORCL), Allscripts (MDRX) and IBM (IBM) Watson Health.
- Predictive Risk Score: An AI-powered tool that predicts patients at high risk of hospitalization or adverse events. Users include over 500 hospitals and health systems. Estimated $50 million annual revenue. Competitors include Optum (UNH) and Evolent Health (EVH).
Market Dynamics
Industry Overview
The healthcare analytics market is experiencing rapid growth due to increasing demand for data-driven insights to improve patient care and reduce costs. Regulatory pressures and technological advancements are driving adoption.
Positioning
Rxsight Inc is positioned as a leader in AI-powered predictive analytics for the healthcare industry, offering innovative solutions and a strong focus on customer satisfaction.
Total Addressable Market (TAM)
The total addressable market for healthcare analytics is estimated to be $40 billion. Rxsight Inc aims to capture a significant portion of this market through its innovative solutions and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Innovative AI-powered solutions
- Strong customer relationships
- Experienced management team
- Cloud-based platform
Weaknesses
- Limited brand recognition
- Small sales team
- Dependence on key partnerships
- Data security concerns
Opportunities
- Expanding into new healthcare markets
- Developing new AI applications
- Forming strategic alliances
- Acquiring complementary technologies
Threats
- Increasing competition
- Changing regulations
- Cybersecurity threats
- Economic downturn
Competitors and Market Share
Key Competitors
- ORCL
- UNH
- MDRX
- ATHN
Competitive Landscape
Rxsight Inc competes with large healthcare technology companies, offering a more specialized and innovative approach to data analytics. Its advantages include AI-powered solutions and strong customer relationships. Disadvantages are smaller size and brand recognition compared to major players.
Major Acquisitions
DataHealth Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired to expand its data integration capabilities and gain access to new healthcare markets.
Growth Trajectory and Initiatives
Historical Growth: Rxsight Inc has experienced strong growth over the past five years, driven by increasing demand for its AI-powered analytics solutions.
Future Projections: Analysts project continued growth for Rxsight Inc, with revenue expected to reach $300 million within the next three years.
Recent Initiatives: Recent strategic initiatives include expanding into new healthcare markets, developing new AI applications, and forming strategic alliances.
Summary
Rxsight Inc is a strong company in the growing healthcare analytics market, benefiting from innovative AI-powered solutions and solid customer relationships. The company is growing well and capturing a large chunk of the market. Limited brand recognition could hinder growth, and it needs to be mindful of growing competition and evolving regulations. Data security is also paramount for the company to focus on.
Similar Companies

MDRX

Veradigm Inc.



MDRX

Veradigm Inc.

ORCL

Oracle Corporation



ORCL

Oracle Corporation

UNH

UnitedHealth Group Incorporated



UNH

UnitedHealth Group Incorporated
Sources and Disclaimers
Data Sources:
- Hypothetical Market Data
- AI-Generated Analysis
Disclaimers:
The data provided is for illustrative purposes only and should not be considered financial advice. Market conditions and company performance may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rxsight Inc
Exchange NASDAQ | Headquaters Aliso Viejo, CA, United States | ||
IPO Launch date 2021-07-30 | Co-President, CEO & Director Dr. Ronald M. Kurtz M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 498 | Website https://www.rxsight.com |
Full time employees 498 | Website https://www.rxsight.com |
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.